group compared with two new cancer events in two patients in the control group treated with autogenous bone graft. The incidence rate of new cancer events per 100 person-years was 3.37 (95% confidence interval [CI], 1.89 to 5.56) in the rhBMP-2/CRM group at two years compared with 0.50 (95% CI, 0.06 to 1.80) in the control group. The incidence rate ratio was 6.75 (95% CI, 1.57 to 60.83; p = 0.0026) at two years. Calculated in terms of the number of patients with one or more cancer events two years after the surgery, the incidence rate per 100 person-years was 2.54 (95% CI, 1.27 to 4.54) in the rhBMP-2/CRM group compared with 0.50 (95% CI, 0.06 to 1.82) in the control group at two years; the incidence rate ratio was 5.04 (95% CI, 1.10 to 46.82; p = 0.0194). At five years, there was a 37% loss of follow-up, but a significantly greater incidence of cancer events was still observed in the rhBMP-2/CRM group.
Conclusions: A high dose of 40 mg of rhBMP-2/CRM in lumbar spinal arthrodesis was associated with an increased risk of new cancer.
Level of Evidence: Therapeutic Level II. See Instructions for Authors for a complete description of levels of evidence.
B
one morphogenetic proteins (BMPs) belong to the transforming growth factor-beta (TGF-beta) superfamily of proteins, which bind to cell-surface receptors and initiate signals that control cell growth, differentiation, and migration. TGF-beta ligands can play roles in either tumor suppression or tumor progression 1 . Thus, there have been concerns that BMP-2 might promote carcinogenesis.
The administration of supraphysiological doses of recombinant human BMP-2 (rhBMP-2) to assist in spinal arthrodesis is relatively new, but an early report indicated that rhBMP-2 could be associated with cancer 2 . Currently, only a small proportion of the rhBMP-2 use in spinal surgery conforms to the indications for use (single-level anterior lumbar arthrodesis utilizing a bovine collagen BMP-2 carrier and anterior Disclosure: None of the authors received payments or services, either directly or indirectly (i.e., via his or her institution), from a third party in support of any aspect of this work. One or more of the authors, or his or her institution, has had a financial relationship, in the thirty-six months prior to submission of this work, with an entity in the biomedical arena that could be perceived to influence or have the potential to influence what is written in this work. Also, one or more of the authors has had another relationship, or has engaged in another activity, that could be perceived to influence or have the potential to influence what is written in this work. The complete Disclosures of Potential Conflicts of Interest submitted by authors are always provided with the online version of the article.
cage fixation) that have been approved by the U.S. Food and Drug Administration (FDA) 3, 4 . In 2006, rhBMP-2 was used in 25% of all spinal arthrodesis procedures in the U.S. 3 . Recently, a pivotal randomized Investigational Device Exemption (IDE) study was performed in which a high-dose rhBMP-2 product, AMPLIFY (Medtronic, Minnesota), was used in patients with single-level degenerative lumbar disease. This product contains 40 mg of rhBMP-2 in a compression-resistant matrix (rhBMP-2/CRM). The IDE study excluded patients with preexisting cancer or a history of cancers 5 . A ''primary outcome measurement'' in that study was the monitoring and comparison of ''serious'' adverse events potentially associated with the implant in the two study arms (treatment with AMPLIFY compared with iliac crest bone graft); such adverse events 1538
included all cancers incident after surgery 5 . Dimar et al. reported on the two-year outcomes of this trial in 2009 and noted eight cancers in the rhBMP-2/CRM group compared with two cancers in the control group 6 . A recent review of that trial by the FDA revealed additional cancers and concluded, ''The primary statistical concern is the apparent association with cancer. In this regard, there were higher rates of cancer events with the rhBMP-2/CRM product in the pivotal study, which were not contradicted by all of the pooled Medtronic trials using rhBMP-2.'' 7 Although this product had not received pre-marketing approval by the FDA as of June 2013, both of the individual elements, rhBMP-2 and the carrier, are currently approved by the FDA to augment lumbar arthrodesis and are available for physician-directed use. High doses of rhBMP-2 in combination with compression-resistant matrix are often used in off-label applications for spinal arthrodesis [3] [4] [5] 7 including multilevel arthrodesis for spinal deformity, revision surgery, and reconstructive procedures. The aim of the present investigation was to determine, using publicly available data from the AMPLIFY pivotal trial, whether high-dose rhBMP-2/CRM was associated with an increased risk of new cancers in patients undergoing lumbar arthrodesis 5, 7, 8 .
Materials and Methods
T he data were obtained via publicly available documents from the FDAapproved IDE study P050036 5, 7, 8 .
Subjects
In the multicenter, prospective, randomized controlled trial comparing AMPLIFY with iliac crest bone graft, patients with degenerative conditions of the lumbar spine were randomized in a 1:1 ratio to receive either autogenous iliac crest bone graft or rhBMP-2 during a single-level instrumented posterolateral arthrodesis. Flowchart of patient recruitment and enrollment in the AMPLIFY trial.
The preparation used in the rhBMP-2/CRM arm contained 2.0 mg/mL of rhBMP-2, for a total dose of 40 mg. The dose was administered utilizing a compressionresistant carrier of type-I bovine collagen, hydroxyapatite, and b-tricalcium phosphate matrix 6 . The randomization block size was four. Two patients crossed over from the control group to the investigational group and were analyzed on an ''as-treated'' basis. Patients and investigators were not blinded regarding the treatment. Patient inclusion and exclusion criteria are listed in the Appendix, and patient flow through the study is shown in Figure 1 . Patients with any active cancer were excluded, as were patients with a remote history of any cancer other than basal cell carcinoma of the skin. The final study population consisted of 239 patients in the rhBMP-2/CRM group and 224 in the control group (see Appendix). All sites had institutional review board (IRB) approval, and the clinical trial was registered at ClinicalTrials.gov (NCT00707265).
Patients were assessed two years after surgery (with the capture period extending to twenty-nine months after surgery) for the primary efficacy and safety analysis. At two years, the follow-up rate for the safety information was 88.28% (n = 211) in the rhBMP-2/CRM group and 83.04% (n = 186) in the control group. Additional yearly follow-up to five years was added, per FDA requirement, after the study began. To our knowledge, this requirement for additional follow-up, which is common in IDE studies, was not triggered by any event. At five years, data were available for 64.85% (155) of the patients in the rhBMP-2/CRM group and 61.16% (137) of those in the control group.
A primary outcome measurement of the IDE study was the monitoring and comparison of serious adverse events potentially associated with the implant. All new cancer events were classified as serious 5 . It was planned that all new cancer events occurring during the clinical trial would be included in the analysis of product safety 5, 7, 8 . Cancer occurrence data (Table I) , including the histopathologic diagnosis and date of diagnosis; surgical, medical, and radiation treatments; and mortality status, were extracted from Adverse Event Case Report Forms.
Statistical Methods
The primary outcome of the present investigation was the number of new (incident) cancer events within the first two years, and the secondary outcome was the number of patients with one or more new cancer events by this time. The primary analysis focused on data collected over the course of the ''two-year follow-up'' interval (extending to twenty-nine months after surgery), which coincided with the preplanned duration of the primary efficacy analysis in the trial. A secondary analysis was performed at approximately five years of followup (fifty-four months and onwards), which was the longest follow-up duration available. The analysis at five years of follow-up was not chosen as the primary analysis since it was not the original study end point, follow-up rates were lower, and some centers did not participate beyond the year-two surveillance.
We calculated incidence rates of new cancer events and of patients with one or more new cancer events on the basis of person-time. For consistency with the FDA adverse event tables, the follow-up time periods were adjusted to match the sponsor and FDA summary tables for cancer and other adverse events 8 . Patients were considered to have multiple cancer events if they had two or more histopathologic diagnoses or if they had the same diagnosis at more than one primary site (e.g., noncontiguous or remote nonmetastatic dermatological cancers) 9, 10 . The person-time denominator was calculated with use of aggregated annual follow-up data provided by the FDA. We used the mid-year population for the first year of follow-up and the end-year population for the remaining years. In calculating the outcome in terms of patients with one or more cancer events, patients were excluded from the person-time denominator at the time they experienced the first event, as they were no longer at risk for becoming a new cancer case.
The incidence rates in the rhBMP-2/CRM and control groups were compared by calculating the incidence rate ratio 11 . The confidence intervals around the incidence rate ratio were constructed with use of the exact approach 11 . The significance of the statistical null hypothesis (H 0 ) that the incidence rate ratio was equal to 1 (i.e., no difference between the rhBMP-2/CRM and control groups) was calculated as twice the one-sided exact significance obtained by the method described by Rothman 11 .
Corroborating statistical analysis was based on survival analysis techniques and used the mean cumulative function approach 12 . The secondary outcome (patients with one or more cancer events) was analyzed with a standard Cox proportional-hazards regression approach. The covariance estimate for the proportional hazards inferences and the global hypothesis testing were based on the robust sandwich estimate of Lin and Wei 13 .
Source of Funding
There was no external funding for this study.
Results
A t two years after surgery, there were fifteen new cancers in eleven patients in the rhBMP-2/CRM group compared with two new cancers in two patients in the control group. At the final follow-up time point, defined as more than fifty-four months, with 63% follow-up, there were twenty new cancers in the rhBMP-2/CRM group compared with five in the control group (Table I) . Three patients in the rhBMP-2/CRM group and none in the control group developed multiple new cancers. One of the patients in the rhBMP-2/CRM group developed three histopathologically different cancers.
The mean age at surgery of the patients who developed a cancer was 59.7 years (range, forty to sixty-nine years) in the rhBMP-2/CRM group and 58.6 years (range, forty-five to seventy-two years) in the control group. The mean time from surgery to the development of the first cancer event in the Over the course of five years, three patients in the rhBMP-2/CRM group were reported to have died of cancer (pancreatic, lung, and ovarian cancer). One patient in the control group died of non-Hodgkin lymphoma. One of the patients in the rhBMP-2/CRM group who developed a new cancer had a remote history of basal cell carcinoma without recurrence. After surgery, this patient was diagnosed with three new cancers: basal cell carcinoma, squamous cell carcinoma of the skin, and chronic myelogenous leukemia.
Incidence Rate of New Cancer Events
At two years after the surgery, the incidence rate of new cancer events per 100 person-years was 3.37 (95% confidence interval [CI], 1.89 to 5.56) in the rhBMP-2/CRM group compared with 0.50 (95% CI, 0.06 to 1.80) in the control group. The incidence rate ratio was 6.75 (95% CI, 1.57 to 60.83; p = 0.0026) ( Table  II) . The hazard ratio was 6.72 (95% CI, 1.46 to 31.03; p = 0.0147). Compared with the control group, the rhBMP-2/CRM group had developed 5.74 additional cancer events per 100 patients at the two-year follow-up time point. In terms of the number needed to harm, one additional cancer event occurred for every 17.4 patients in the AMPLIFY group within two years of follow-up after the surgery.
Five years after the surgery, the incidence rate of new cancer events was 2.15 (95% CI, 1.31 to 3.32) per 100 personyears in the rhBMP-2/CRM group compared with 0.60 (95% CI, 0.19 to 1.39) in the control group. The incidence rate ratio was 3.60 (95% CI, 1.31 to 12.28; p = 0.0055). The hazard ratio was 3.59 (95% CI, 1.16 to 11.13; p = 0.0266). Figure 2 shows the mean cumulative function for new cancer events per patient. Because the mean cumulative function accounts for the possibility that multiple cancers can occur in a single patient, Cumulative hazards for patients with one or more cancer events.
1541
T
this graph reflects the multiple cancer events that occurred in three patients in the rhBMP-2/CRM group. Thus, by year five, a mean of 10.55 new cancer events per 100 patients occurred in the rhBMP-2/CRM group compared with 2.93 new cancer events per 100 patients in the control group.
Incidence Rate of Patients with One or More Cancer Events
When the outcome was expressed relative to the total number of patients treated, 4.6% of the rhBMP-2/CRM group developed cancer by year two compared with 0.9% of the control group (p = 0.022, two-tailed Fisher exact test). The incidence rate of patients with one or more cancer events two years after the surgery was 2.54 (95% CI, 1.27 to 4.54) per 100 personyears in the rhBMP-2/CRM group compared with 0.50 (95% CI, 0.06 to 1.82) per 100 person-years in the control group. The incidence rate ratio was 5.04 (95% CI, 1.10 to 46.82; p = 0.0194). The hazard ratio was 5.09 (95% CI, 1.13 to 23.05, p = 0.0347). Figure 3 shows the cumulative hazards for patients with one or more cancer events. In the two years after exposure, an additional 4.06% of the patients in the rhBMP-2/CRM group developed cancer compared with the control group; the number needed to harm was 24.6 patients.
Five years after the surgery, the incidence rate of patients with one or more cancer events was 1.36 (95% CI, 0.70 to 2.37) per 100 person-years in the rhBMP-2/CRM group compared with 0.61 (95% CI, 0.20 to 1.41) per 100 person-years in the control group. The incidence rate ratio was 2.24 (95% CI, 0.74 to 8.12; p = 0.1267). The hazard ratio was 2.23 (95% CI, 0.79 to 6.30, p = 0.1315).
Cumulative Incidence
The cumulative incidence of cancer events in the rhBMP-2/ CRM group showed a steep increase during the first two years (Fig. 4) . After two years, the cumulative incidences in the rhBMP-2/CRM and control groups had similar slopes. At five years, the cumulative incidence of cancer events per 100 patients was 10.75 in the rhBMP-2/CRM group and 2.99 in the control group. The difference cancer events per 100 patients over five years of exposure was 7.77 (95% CI, 2.38 to 13.16; p = 0.0055). Thus, for every 100 patients exposed to high-dose rhBMP-2, 7.77 additional cancer events occurred over five years compared with control patients. The cumulative incidence of patients with one or more cancer events is shown in Figure 5 . Again, the incidence in the rhBMP-2/CRM group showed a steep increase during the first two years. Cumulative incidence of cancer events. Cumulative incidence of patients with one or more cancer events.
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Discussion T he use of a supraphysiological dose of rhBMP-2 for spinal arthrodesis raises concerns that this potent growth factor may pose a risk of cancer. The incidence of cancer associated with rhBMP-2 exposure has been difficult to determine and rhBMP-2, as used in common clinical practice, lacks the safety data usually required for FDA approval of a new drug.
The 86% two-year follow-up rate in the present study suggests a high level of confidence in the analysis of differences between the test groups during this period. At two years after exposure to rhBMP-2/CRM, both the occurrence of any cancer in the per-patient analysis and the total number of cancers in the per-event analysis were markedly and significantly greater than those observed in the control group. The incidence rate of cancers was 6.8-fold greater in the rhBMP-2/ CRM group compared with the control group (p = 0.0026). When multiple cancers in a single subject were not considered, 5.0-fold more patients developed one or more cancers in the rhBMP-2/CRM group compared with the control group (p = 0.0194). For every 17.4 patients in the rhBMP-2/CRM group, one additional cancer event occurred by two years after the surgery.
Dimar et al. analyzed two-year data from the same trial. They reported eight new cancer events in the rhBMP-2 group at that time 6 . The difference between our analysis and that of Dimar et al. may arise from identification of additional cancer events since that report, including an analysis of multiple cancer events, and from a possible difference in adverse event analysis in the context of drug compared with device evaluations.
There are plausible biological explanations for the apparent association of rhBMP-2/CRM with cancer. TGF-beta signaling pathways play complex, context-dependent roles, and disruption of the balance in signaling can lead to tumorigenesis 14, 15 . In early stages of carcinogenesis, TGF-beta functions as a tumor suppressor. However, in a later stage after other oncogenic events, such as activation of Ras or mutation of p53, TGF-beta can switch to a potent pro-metastatic pathway 16 . TGF-beta ligands can drive tumor invasion by inducing an epithelial-to-mesenchymal transition 17 , disrupting capillary walls to promote lung metastases 18 , and driving self-renewal and tumorigenicity of cancer stem cells 19 . More specifically, BMP-2 may play a role in tumor progression. In tissue culture, BMP-2 stimulates the invasiveness of pancreatic and breast cancer cells [20] [21] [22] and the epithelial-tomesenchymal transition in lung cancer 23 . BMP-2 affects the expression of many genes, including notable changes in apoptosis genes 24 . In a colon cancer cell line, BMP-2 initially suppresses growth mildly, but after prolonged treatment it becomes growth-stimulatory, suppressing PTEN via RAS/ERK signaling 25 . In mouse xenograft models, BMP-2 stimulates breast cancer invasion 26 , formation of osteoblastic and osteolytic lesions from prostate cancer cells 21, 27 and angiogenesis in lung and breast cancer cells 28, 29 . The outcomes in these studies are consistent with the short time lag documented between rhBMP-2 exposure and cancer diagnoses in the present human trial. The rapid appearance of new cancers raises the possibility that rhBMP-2 may have acted as a cancer promoter, stimulating the growth and aggressiveness of preexisting, subclinical and less malignant tumors.
The relative increase in the incidence of skin cancers diagnosed following BMP-2/CRM exposure may reflect the ease of diagnosis of these cancers if growth was accelerated. These cancers are also associated with sun exposure, and a disproportionate effect in the BMP-2 group might also have resulted from an imbalance in patient enrollment by geographic site. Examination of actual enrollment data for the twenty-nine sites 5, 7 , however, confirmed that no site enrolled an excess of more than two patients of either group.
This study does not address the mechanism by which locally delivered rhBMP-2/CRM may promote remote cancer. However, endogenous BMP-2 normally exists in extremely small qualities (0.1 ng/mL) 7 . The implanted concentration of rhBMP-2 is one to twenty million times ambient concentrations 5, 7, 30 . Small increases in BMP-2 exposure to quiescent malignant cells in distant locations may alter immune or genetic controls of in situ disease. Supraphysiological BMP-2 concentrations may also have immune or neurologically mediated effects through second messengers or neuro-signaling pathways (e.g., BMP-2 exposure produces antibodies in 3% to 7% of patients treated with rhBMP-2) 30 . Furthermore, the retention time of rhBMP-2 is increased by use of the CRM carrier compared with collagen sponges in vivo, possibly increasing the duration of potential exposure 5, 30 . The present analysis is based on Level-II evidence (a single, randomized controlled trial with no blinding). Although the estimates of cancer risk at two years suggest that the analysis of the data may be highly reliable, declining follow-up rates and loss of participation of some study centers could have impacted the three to five-year estimates. Within the first two years, there was a small differential loss to followup between the groups, and the effect of this differential loss is unknown. The assumption made in our analytical approach is that the patients who were lost to follow-up had a risk of cancer similar to that of the patients who remained in the study. We addressed the robustness of our primary statistical approach by performing alternative calculations based on statistical analysis of cancer-free survival and adjusting for the interdependence of observations involving recurrent events in the same patients, as this approach does not rely on the assumption of constant hazards 31 . The results of the survival analysis corroborated the person-time incidence results. Given the discrete nature of the follow-up, which occurred at annually spaced follow-up points after twelve months, our available data provide a reasonable estimate of the population at risk. Another specific limitation of the study involves the possibility that the rhBMP-2 group had been systematically followed more closely for cancer.
When interpreting the results of this study, it should be recognized that the cancer risk estimates reported apply to use of a relatively high rhBMP-2 dose in patients selected for comparatively low cancer risk. The cancer risk associated with BMP-2 exposure may be greater in populations with a higher prevalence of indolent or in situ cancer (e.g., older individuals, those with a history of cancer or a known concurrent cancer, and those with genetic or exposure-related predispositions). Conversely, the present study does not address the risk of cancer associated with lower doses of rhBMP-2 or with rhBMP-2 in a different carrier matrix. However, the FDA analysis of all Medtronic spinal trials (involving a variety of doses and carriers) indicated that the pooled data were consistent with the results of this high-dose trial 7 . In summary, use of 40 mg of rhBMP-2/CRM in lumbar arthrodesis was associated with an increased risk of new cancers. This finding raises important concerns because of the large number of patients currently being exposed to rhBMP-2 at high doses in off-label use. Further analysis of the cancer risk associated with rhBMP-2 therapy is warranted.
